Moreover the efficacy of Prasugrel, another P2Y12 receptor blocker, in abolishing pro-thrombotic and pro-inflammatory responses of platelets and CD4+ T cells in humans, may also provide an indirect positive effect on the inflammatory response underlying the genesis of atheroma and also in cardiovascular diseases involving T cells (125). Here, CD4 is linked to cardiovascular disorder.